Skip Navigation



Annals of Oncology Advance Access published online on November 4, 2009
Annals of Oncology, doi:10.1093/annonc/mdp472
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Overkleeft, E. N. M.
Right arrow Articles by Verheul, H. M. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Overkleeft, E. N. M.
Right arrow Articles by Verheul, H. M. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letter to the editor

Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib

The first 10% of the full text of this article appears below.

We report a 50-year-old man, diagnosed with advanced renal cell carcinoma (RCC), who was treated with sunitinib for 7 months until progression. Sorafenib was started as second-line treatment 2 weeks later. Within 10 days after initiation of sorafenib treatment, the patient developed skin rash with erythema, influenza-like symptoms, hypertension, generalized edema and oliguria. Renal failure with a serum creatinine level of 306 µmol/l, proteinuria of 20 g/24 h . . . [Full Text of this Article]

disclosure

E. N. M. Overkleeft1,*, R. Goldschmeding1, F. van Reekum1, E. E. Voest1 and H. M. W. Verheul2

1 Department of Medical Oncology, University Medical Center Utrecht, Utrecht
2 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

* (E-mail: e.overkleeft@umcutrecht.nl)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?